News
PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis
Enrollment of 950 Patients, the Minimum Number of Patients Targeted for the SHIELD I Study, Expected Within Days Top-line Results Expected by End of Q3 2022; Potential NDA and MAA Submissions Targeted for H1 2023 Conference Call Scheduled for Today at 8:30 a.m. ET...
PolyPid Provides Corporate Update and Reports First Quarter 2022 Financial Results
Planned Unblinded Interim Analysis of Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Soft Tissue Surgery Expected to Occur Imminently Recruitment Progressing as Planned with Approximately 900 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal...
PolyPid to Report First Quarter 2022 Financial Results and Operational Highlights on May 11, 2022
PETACH TIKVA, Israel, April 27, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2022 financial results and operational...
PolyPid Announces Presentation at the 13th European and Global CLINAM Summit for Nanomedicine
Presentation evaluates the effect of D-PLEX100 in limiting occurrence of antimicrobial resistance (AMR) in colorectal surgery patients PETACH TIKVA, Israel, April 25, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company...
PolyPid Announces Presentation of Clinical Data at Surgical Infection Society 2022 Annual Meeting
Presentation evaluates the addition of D-PLEX to the surgical site infection standard of care prophylaxis regimen in elective colorectal surgeryPETACH TIKVA, Israel, April 12, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma...
PolyPid Secures $15 Million Non-Dilutive Secured Term Loan Facility
Secured Loan facility with Kreos Capital Extends Company's Cash Runway into the Second Quarter of 2023PETACH TIKVA, Israel, April 06, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes,...
PolyPid to Deliver Poster Presentation at SAGES 2022
Presentation Evaluates Efficacy of D-PLEX100 in Reducing Surgical Site Infection Rates in Elective Colorectal Surgery PETACH TIKVA, Israel, March 08, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve...
PolyPid Announces 750th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX in Abdominal Surgery
Unblinded Interim Analysis Expected in the Second Quarter of 2022PETACH TIKVA, Israel, March 02, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and...
PolyPid to Present at the Barclays Global Healthcare Conference
PETACH TIKVA, Israel, March 01, 2022 -- PolyPid Ltd. (Nasdaq: PYPD), ("PolyPid" or the "Company"), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today...
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results
FDA Agreed to PolyPid Request for the Addition of an Unblinded Interim Analysis in SHIELD I once 750 Patients Complete their 30-day Follow-up Recruitment Progressing as Planned with Approximately 680 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in...